NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: yesterday, 9:04AM

52.03

-0.53 (-1.01%)

  • 1D -1.01%
  • 5D 9.29%
  • 1M 5.43%
  • 6M -24.61%
  • YTD -40.55%
  • 1Y -39.31%
  • 5Y 48.13%
Previous Close 52.56
Open 53.02
Volume 3,127,572
Avg. Volume (3M) 17,299,051
Market Cap 231,199,571,968
Price / Earnings (TTM) 14.14
Price / Earnings (Forward) 13.00
Price / Sales 4.27
Price / Book 7.92
52 Weeks Range
43.08 (-17%) — 93.80 (80%)
Earnings Date 4 Feb 2026
TTM Dividend Yield 2.11%
Profit Margin 34.51%
Operating Margin (TTM) 49.68%
Diluted EPS (TTM) 3.67
Quarterly Revenue Growth (YOY) 19.50%
Quarterly Earnings Growth (YOY) 14.30%
Total Debt/Equity (MRQ) 85.70%
Current Ratio (MRQ) 0.740
Operating Cash Flow (TTM) 131.24 B
Levered Free Cash Flow (TTM) 77.73 B
Return on Assets (TTM) 23.29%
Return on Equity (TTM) 88.12%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bearish
Drug Manufacturers - General (Global) Mixed Bearish
Stock Novo Nordisk A/S Bearish Bearish

AIStockmoo Score

1.4
Analyst Consensus -3.5
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 1.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NVO 231 B 2.11% 14.14 7.92
NVS 263 B 3.27% 18.72 6.02
LLY 962 B 0.14% 52.50 40.54
JNJ 500 B 0.60% 20.08 6.31
ABBV 406 B 1.43% 175.56 50.46
MRK 266 B 1.52% 14.08 4.84

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Insiders 0.01%
% Held by Institutions 9.85%

Ownership

Name Date Shares Held
Fayez Sarofim & Co 30 Sep 2025 7,353,587
Everett Harris & Co /Ca/ 30 Sep 2025 6,393,780
52 Weeks Range
43.08 (-17%) — 93.80 (80%)
Price Target Range
46.00 (-11%) — 70.00 (34%)
High 70.00 (HSBC, 34.54%) Buy
Median 50.50 (-2.94%)
Low 46.00 (BMO Capital, -11.59%) Hold
Average 54.25 (4.26%)
Total 2 Buy, 1 Hold, 1 Sell
Avg. Price @ Call 52.66
Firm Date Target Price Call Price @ Call
Goldman Sachs 28 Nov 2025 54.00 (3.78%) Buy 49.35
BMO Capital 25 Nov 2025 46.00 (-11.59%) Hold 47.06
14 Oct 2025 55.00 (5.71%) Hold 56.66
HSBC 02 Oct 2025 70.00 (34.53%) Buy 58.74
Morgan Stanley 29 Sep 2025 47.00 (-9.67%) Sell 55.50

No data within this time range.

  • 3M
Date Type Details
22 Dec 2025 Announcement Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22 Dec 2025 CNBC FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
19 Dec 2025 CNBC Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple
12 Dec 2025 Announcement Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
11 Dec 2025 CNBC Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  
09 Dec 2025 Announcement Novo Nordisk has completed its acquisition of Akero Therapeutics
01 Dec 2025 CNBC Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
25 Nov 2025 Announcement Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
24 Nov 2025 Announcement Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
24 Nov 2025 CNBC Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
17 Nov 2025 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
17 Nov 2025 CNBC Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
14 Nov 2025 Announcement Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
13 Nov 2025 Announcement Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
11 Nov 2025 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2025 Announcement Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 
07 Nov 2025 CNBC Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025 CNBC Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025 Announcement Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
06 Nov 2025 Announcement Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
06 Nov 2025 CNBC Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
05 Nov 2025 Announcement Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
05 Nov 2025 Announcement Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
04 Nov 2025 CNBC Pfizer tops estimates, raises profit guidance even as sales fall
04 Nov 2025 CNBC Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
04 Nov 2025 Announcement Novo Nordisk submits updated proposal to acquire Metsera, Inc.
04 Nov 2025 Announcement /C O R R E C T I O N -- Metsera, Inc./
03 Nov 2025 CNBC Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
02 Nov 2025 CNBC Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025 CNBC Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
30 Oct 2025 Announcement Novo Nordisk submits proposal to acquire Metsera, Inc.
30 Oct 2025 Announcement Metsera Receives Unsolicited Proposal from Novo Nordisk
29 Oct 2025 CNBC Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
21 Oct 2025 Announcement Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
21 Oct 2025 Announcement Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 Announcement Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
09 Oct 2025 Announcement Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
30 Sep 2025 Announcement SueWallSt Podcast Series Launches With Focus on Novo Nordisk A/S (NVO) Fraud Allegations
29 Sep 2025 Announcement Novo Nordisk A/S (NVO) Shareholders Get Answers in Latest SueWallSt Podcast
Show more
TTM Dividend Yield 2.11%
5Y Average Dividend Yield 2.48%
Payout Ratio 47.09%
Expected Next Dividend Payment Apr 2026
Ex Date Announcement Date Payment Date Details
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Cash
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Cash
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Cash
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Cash
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Cash
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Cash
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Cash
16 Aug 2021 - 25 Aug 2021 0.5502889 Cash
26 Mar 2021 - 07 Apr 2021 0.922122 Cash
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Cash
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Cash
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Cash
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Cash
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Cash
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Cash
17 Aug 2017 - 29 Aug 2017 0.33589 Cash
23 Mar 2017 - 04 Apr 2017 0.479369 Cash
11 Aug 2016 - 23 Aug 2016 0.331026 Cash
18 Mar 2016 - 30 Mar 2016 0.69943 Cash
19 Mar 2015 - 31 Mar 2015 0.532885 Cash
21 Mar 2014 - 02 Apr 2014 0.606122 Cash
21 Mar 2013 - 02 Apr 2013 2.264307 Cash
22 Mar 2012 - 03 Apr 2012 1.831902 Cash
24 Mar 2011 - 05 Apr 2011 1.357901 Cash
25 Mar 2010 - 07 Apr 2010 0.978615 Cash
19 Mar 2009 - 31 Mar 2009 0.781532 Cash
13 Mar 2008 - 25 Mar 2008 0.678462 Cash
08 Mar 2007 - 20 Mar 2007 0.891779 Cash
09 Mar 2006 - 21 Mar 2006 0.691753 Cash
10 Mar 2005 - 22 Mar 2005 0.61725 Cash
17 Mar 2004 - 29 Mar 2004 0.52096 Cash
26 Mar 2003 - 07 Apr 2003 0.37647 Cash
13 Mar 2002 - 25 Mar 2002 0.2848 Cash
21 Mar 2001 - 02 Apr 2001 0.5681 Cash
24 Mar 2000 - 06 Apr 2000 0.4672 Cash
25 Mar 1999 - 06 Apr 1999 0.4182 Cash
27 Mar 1998 - 08 Apr 1998 0.3051 Cash
25 Apr 1997 - 07 May 1997 0.239 Cash
01 May 1996 - 14 May 1996 0.1806 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.10 1 2.11
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria